Members Sought for Director's Consumer Liaison Group: NCI
BETHESDA, Md--The NCI is calling for nominations for a new initiative--the Director's Consumer Liaison Group (DCLG). This group will help the NCI increase the representation of the cancer advocacy community on NCI advisory committees and increase the involvement of consumer advocates in program and policy development.
BETHESDA, Md--The NCI is calling for nominations for a new initiative--theDirector's Consumer Liaison Group (DCLG). This group will help the NCIincrease the representation of the cancer advocacy community on NCI advisorycommittees and increase the involvement of consumer advocates in programand policy development.
It will consist of 15 consumer advocates brought together from manyadvocacy communities. To be eligible for the DCLG, a nominee must be involvedin the cancer experience as a cancer survivor, a person affected by thesuffering and consequences of cancer, or a professional/volunteer who workswith survivors or those affected.
Nominations can be made by organizations, including local/regional andnational groups, or by individuals, including self-nominations.
For more information and to receive a nomination package, send yourname, advocacy organization affiliation (if any), and address to the Officeof Liaison Activities, NCI, c/o Palladian Partners, 7315 Wisconsin Avenue,Suite 440W, Bethesda, MD 20814. Fax: 301-986-5047. Nominations must bepostmarked by September 15, 1997.
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
